Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
Volume 8, Issue 6, Pages 691-707Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2015.1090874
Keywords
avibactam; ceftazidime; complicated intra-abdominal infections; complicated urinary tract infections; multidrug resistance
Categories
Funding
- AstraZeneca
- Forest Laboratories LLC.
Ask authors/readers for more resources
Treatment of complicated urinary tract infections and complicated intra-abdominal infections is increasingly difficult due to the rising prevalence of multidrug-resistant Gram-negative bacteria. Ceftazidime-avibactam is a combination of the established third-generation cephalosporin ceftazidime with avibactam, a novel non--lactam -lactamase inhibitor, which restores the activity of ceftazidime against many -lactamase-producing Gram-negative bacteria, including extended-spectrum -lactamases and Klebsiella pneumoniae carbapenemases. Clinical and nonclinical studies supporting the safety and efficacy of ceftazidime-avibactam include microbiological surveillance studies of clinically relevant pathogens, in vivo animal models of infection, pharmacokinetic/pharmacodynamic target attainment analyses, Phase I clinical pharmacology studies, and Phase II/III studies in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including patients with ceftazidime-nonsusceptible Gram-negative infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available